<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35118917</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>08</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1365-2060</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>54</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Annals of medicine</Title>
          <ISOAbbreviation>Ann Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis.</ArticleTitle>
        <Pagination>
          <StartPage>516</StartPage>
          <EndPage>523</EndPage>
          <MedlinePgn>516-523</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/07853890.2022.2034936</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">The coronavirus disease (COVID-19) epidemic has not been completely controlled. Although great achievements have been made in COVID-19 research and many antiviral drugs have shown good therapeutic effects against COVID-19, a simple oral antiviral drug for COVID-19 has not yet been developed. We conducted a meta-analysis to investigate the improvement in mortality or hospitalization rates and adverse events among COVID-19 patients with three new oral antivirals (including molnupiravir, fluvoxamine and Paxlovid).</AbstractText>
          <AbstractText Label="METHODS">We searched scientific and medical databases, such as PubMed, Web of Science, Embase and Cochrane Library for relevant articles and screened the references of retrieved studies on COVID-19.</AbstractText>
          <AbstractText Label="RESULTS">A total of eight studies were included in this study. The drug group included 2440 COVID-19 patients, including 54 patients who died or were hospitalized. The control group included a total of 2348 COVID-19 patients, including 118 patients who died or were hospitalized. The overall odds ratio (OR) of mortality or hospitalization was 0.33 (95% confidence interval [CI], 0.22-0.49) for COVID-19 patients in the drug group and placebo group, indicating that oral antiviral drugs were effective for COVID-19 patients and reduced the mortality or hospitalization by approximately 67%.</AbstractText>
          <AbstractText Label="CONCLUSIONS">This study showed that three novel oral antivirals (molnupiravir, fluvoxamine and Paxlovid) are effective in reducing the mortality and hospitalization rates in patients with COVID-19. In addition, the three oral drugs did not increase the occurrence of adverse events, thus exhibiting good overall safety. These three oral antiviral drugs are still being studied, and the available data suggest that they will bring new hope for COVID-19 recovery and have the potential to be a breakthrough and very promising treatment for COVID-19.KEY MESSAGESMany antiviral drugs have shown good therapeutic effects, and there is no simple oral antiviral drug for COVID-19 patients.Meta-analysis was conducted for three new oral antivirals to evaluate the improvement in mortality or hospitalization rates and adverse events among COVID-19 patients.We focussed on three new oral Coronavirus agents (molnupiravir, fluvoxamine and Paxlovid) and hope to provide guidance for the roll-out of oral antivirals.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wen</LastName>
            <ForeName>Wen</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Hangzhou Institute of Cardiovascular Diseases, Affiliated Hospital of Hangzhou Normal University, Hangzhou, PR China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Hangzhou Normal University, Hangzhou, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Chen</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Hangzhou Institute of Cardiovascular Diseases, Affiliated Hospital of Hangzhou Normal University, Hangzhou, PR China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Hangzhou Normal University, Hangzhou, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Jiake</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Hangzhou Institute of Cardiovascular Diseases, Affiliated Hospital of Hangzhou Normal University, Hangzhou, PR China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Hangzhou Normal University, Hangzhou, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Chunyi</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Hangzhou Institute of Cardiovascular Diseases, Affiliated Hospital of Hangzhou Normal University, Hangzhou, PR China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Hangzhou Normal University, Hangzhou, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Mengyun</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular and Cellular Physiology, Shinshu University School of Medicine, Matsumoto, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cheng</LastName>
            <ForeName>Yongran</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>School of Public Health, Hangzhou Medical College, Hangzhou, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Xiang</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Hangzhou Institute of Cardiovascular Diseases, Affiliated Hospital of Hangzhou Normal University, Hangzhou, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Qi</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Hangzhou Institute of Cardiovascular Diseases, Affiliated Hospital of Hangzhou Normal University, Hangzhou, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Xingwei</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Hangzhou Institute of Cardiovascular Diseases, Affiliated Hospital of Hangzhou Normal University, Hangzhou, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Feng</LastName>
            <ForeName>Zhanhui</ForeName>
            <Initials>Z</Initials>
            <Identifier Source="ORCID">0000-0003-4755-7415</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Affiliated Hospital of Guizhou Medical University, Guiyang, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Mingwei</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0001-9060-5107</Identifier>
            <AffiliationInfo>
              <Affiliation>Hangzhou Institute of Cardiovascular Diseases, Affiliated Hospital of Hangzhou Normal University, Hangzhou, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mao</LastName>
            <ForeName>Qin</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Hangzhou Institute of Cardiovascular Diseases, Affiliated Hospital of Hangzhou Normal University, Hangzhou, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D017418">Meta-Analysis</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Ann Med</MedlineTA>
        <NlmUniqueID>8906388</NlmUniqueID>
        <ISSNLinking>0785-3890</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006898">Hydroxylamines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007769">Lactams</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009570">Nitriles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000719967">nirmatrelvir and ritonavir drug combination</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5CSZ8459RP</RegistryNumber>
          <NameOfSubstance UI="D003562">Cytidine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9DLQ4CIU6V</RegistryNumber>
          <NameOfSubstance UI="D011392">Proline</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>GMW67QNF9C</RegistryNumber>
          <NameOfSubstance UI="D007930">Leucine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>O3J8G9O825</RegistryNumber>
          <NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>O4L1XPO44W</RegistryNumber>
          <NameOfSubstance UI="D016666">Fluvoxamine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>YA84KI1VEW</RegistryNumber>
          <NameOfSubstance UI="C000656703">molnupiravir</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <SupplMeshList>
        <SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003562" MajorTopicYN="N">Cytidine</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016666" MajorTopicYN="Y">Fluvoxamine</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006898" MajorTopicYN="N">Hydroxylamines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007769" MajorTopicYN="N">Lactams</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007930" MajorTopicYN="N">Leucine</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009570" MajorTopicYN="N">Nitriles</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011392" MajorTopicYN="N">Proline</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">COVID-19</Keyword>
        <Keyword MajorTopicYN="Y">Paxlovid™</Keyword>
        <Keyword MajorTopicYN="Y">fluvoxamine</Keyword>
        <Keyword MajorTopicYN="Y">molnupiravir</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>4</Day>
          <Hour>8</Hour>
          <Minute>41</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35118917</ArticleId>
        <ArticleId IdType="pmc">PMC8820829</ArticleId>
        <ArticleId IdType="doi">10.1080/07853890.2022.2034936</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>WHO . Coronavirus (COVID-19) data . [cited 2021 Nov 12]. Available from: https://www.who.int/data#reports</Citation>
        </Reference>
        <Reference>
          <Citation>Rivasi G, Bulgaresi M, Mossello E, et al. . 
Course and lethality of SARS-CoV-2 epidemic in nursing homes after vaccination in Florence, Italy. Vaccines (Basel). 2021;9(10):1174.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8537408</ArticleId>
            <ArticleId IdType="pubmed">34696282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>National health commission of the people's republic of China. [cited 2021 Nov 12]. Available from: http://www.nhc.gov.cn/jkj/s7915/202111/fc017abab2af4dfbbe5b4f0bdcbf8795.shtml</Citation>
        </Reference>
        <Reference>
          <Citation>Imran M, Kumar Arora M, Asdaq SMB, et al. . 
Discovery, development, and patent trends on molnupiravir: a prospective oral treatment for COVID-19. Molecules. 2021;26(19):5795.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8510125</ArticleId>
            <ArticleId IdType="pubmed">34641339</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Christie A, Mbaeyi SA, Walensky RP.. 
CDC interim recommendations for fully vaccinated people: an important first step. JAMA. 2021;325(15):1501–1502.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33688914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vitiello A, Troiano V, La Porta R.. 
What will be the role of molnupiravir in the treatment of COVID-19 infection?
Drugs Ther Perspect. 2021;37(12):572–579.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8570236</ArticleId>
            <ArticleId IdType="pubmed">34754175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferner RE, Aronson JK.. 
Remdesivir in covid-19. BMJ. 2020;369:m1610.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32321732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vitiello A, Ferrara F, Porta R. Remdesivir and COVID-19 infection, therapeutic benefits or unnecessary risks? Ir J Med Sci. 2021;190(4):1637–1638.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7801863</ArticleId>
            <ArticleId IdType="pubmed">33433843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Menéndez-Arias L.
Decoding molnupiravir-induced mutagenesis in SARS-CoV-2. J Biol Chem. 2021;297(1):100867.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8188802</ArticleId>
            <ArticleId IdType="pubmed">34118236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao J, Guo S, Yi D, et al. . 
A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase. Antiviral Res. 2021;190:105078.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8059291</ArticleId>
            <ArticleId IdType="pubmed">33894278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agostini ML, Pruijssers AJ, Chappell JD, et al. . 
Small-Molecule antiviral β-d- N 4-Hydroxycytidine inhibits a Proofreading-Intact coronavirus with a high genetic barrier to resistance. J Virol. 2019;93(24):e01348–19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6880162</ArticleId>
            <ArticleId IdType="pubmed">31578288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosenke K, Hansen F, Schwarz B, et al. . 
Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model. Nat Commun. 2021;12(1):2295.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8052374</ArticleId>
            <ArticleId IdType="pubmed">33863887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sheahan TP, Sims AC, Zhou S, et al. . 
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Trans Med. 2020;12(541):eabb5883.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7164393</ArticleId>
            <ArticleId IdType="pubmed">32253226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fischer W, Eron JJ, Holman W, et al. . 
Molnupiravir, an oral antiviral treatment for COVID-19. medRxiv. 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Mahase E.
Covid-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports. BMJ. 2021;375:n2422.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34607801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calusic M, Marcec R, Luksa L, et al. . 
Safety and efficacy of fluvoxamine in COVID-19 ICU patients: an open label, prospective cohort trial with matched controls. Br J Clin Pharmacol. 2021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8653355</ArticleId>
            <ArticleId IdType="pubmed">34719789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seftel D, Boulware DR.. 
Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19. Open Forum Infect Dis. 2021;8(2):ofab050.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7888564</ArticleId>
            <ArticleId IdType="pubmed">33623808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lenze EJ, Mattar C, Zorumski CF, et al. . 
Fluvoxamine vs. placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA. 2020;324(22):2292–2300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7662481</ArticleId>
            <ArticleId IdType="pubmed">33180097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reis G, Dos Santos Moreira-Silva EA, Silva DCM, et al. . 
Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health. 2022;10(1):e42–e51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8550952</ArticleId>
            <ArticleId IdType="pubmed">34717820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pfizer’s novel COVID-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study . 2021. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate</Citation>
        </Reference>
        <Reference>
          <Citation>Hetero announces interim clinical results from phase III clinical trials of molnupiravir conducted in India . 2021. Available from: https://c19mp.com/hetero.html</Citation>
        </Reference>
        <Reference>
          <Citation>Singh AK, Singh A, Singh R, et al. . 
Molnupiravir in COVID-19: a systematic review of literature. Diabetes Metab Syndr. 2021;15(6):102329.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8556684</ArticleId>
            <ArticleId IdType="pubmed">34742052</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toots M, Yoon JJ, Hart M, et al. . 
Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model. Trans Res. 2020;218:16–28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7568909</ArticleId>
            <ArticleId IdType="pubmed">31945316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kabinger F, Stiller C, Schmitzová J, et al. . 
Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat Struct Mol Biol. 2021;28(9):740–746.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8437801</ArticleId>
            <ArticleId IdType="pubmed">34381216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou S, Hill CS, Sarkar S, et al. . 
β-d-N4-hydroxycytidine inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells. J Infect Dis. 2021;224(3):415–419.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8136050</ArticleId>
            <ArticleId IdType="pubmed">33961695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sukhatme VP, Reiersen AM, Vayttaden SJ, et al. . 
Fluvoxamine: a review of its mechanism of action and its role in COVID-19. Front Pharmacol. 2021;12:652688.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8094534</ArticleId>
            <ArticleId IdType="pubmed">33959018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>8 Lingering questions about the new Covid pills from Merck and Pfizer . [cited 2021 Nov 16]. Available from: https://www.statnews.com/2021/11/15/8-lingering-questions-about-the-new-covid-pills-from-merck-and-pfizer/</Citation>
        </Reference>
        <Reference>
          <Citation>Pfizer seeks emergency use authorization for novel COVID-19 oral antiviral candidate . Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-seeks-emergency-use-authorization-novel-covid-19</Citation>
        </Reference>
        <Reference>
          <Citation>Painter WP, Holman W, Bush JA, et al. Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel Broad-Spectrum oral antiviral agent with activity against SARS-CoV-2. Antimicrob Agents Chemother. 2021;65(5):e02428–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8092915</ArticleId>
            <ArticleId IdType="pubmed">33649113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pormohammad A, Zarei M, Ghorbani S, et al. . 
Efficacy and safety of COVID-19 vaccines: a systematic review and Meta-Analysis of randomized clinical trials. Vaccines (Basel). 2021;9(5):467.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8148145</ArticleId>
            <ArticleId IdType="pubmed">34066475</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharif N, Alzahrani KJ, Ahmed SN, et al. . 
Efficacy, immunogenicity and safety of COVID-19 vaccines: a systematic review and Meta-Analysis. Front Immunol. 2021;12:714170.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8542872</ArticleId>
            <ArticleId IdType="pubmed">34707602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wibmer CK, Ayres F, Hermanus T, et al. . 
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med. 2021;27(4):622–625.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33654292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia-Beltran WF, Lam EC, St Denis K, et al. . 
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021;184(9):2372–2383.e9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7953441</ArticleId>
            <ArticleId IdType="pubmed">33743213</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35118917</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>08</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1365-2060</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>54</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Annals of medicine</Title>
          <ISOAbbreviation>Ann Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis.</ArticleTitle>
        <Pagination>
          <StartPage>516</StartPage>
          <EndPage>523</EndPage>
          <MedlinePgn>516-523</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/07853890.2022.2034936</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">The coronavirus disease (COVID-19) epidemic has not been completely controlled. Although great achievements have been made in COVID-19 research and many antiviral drugs have shown good therapeutic effects against COVID-19, a simple oral antiviral drug for COVID-19 has not yet been developed. We conducted a meta-analysis to investigate the improvement in mortality or hospitalization rates and adverse events among COVID-19 patients with three new oral antivirals (including molnupiravir, fluvoxamine and Paxlovid).</AbstractText>
          <AbstractText Label="METHODS">We searched scientific and medical databases, such as PubMed, Web of Science, Embase and Cochrane Library for relevant articles and screened the references of retrieved studies on COVID-19.</AbstractText>
          <AbstractText Label="RESULTS">A total of eight studies were included in this study. The drug group included 2440 COVID-19 patients, including 54 patients who died or were hospitalized. The control group included a total of 2348 COVID-19 patients, including 118 patients who died or were hospitalized. The overall odds ratio (OR) of mortality or hospitalization was 0.33 (95% confidence interval [CI], 0.22-0.49) for COVID-19 patients in the drug group and placebo group, indicating that oral antiviral drugs were effective for COVID-19 patients and reduced the mortality or hospitalization by approximately 67%.</AbstractText>
          <AbstractText Label="CONCLUSIONS">This study showed that three novel oral antivirals (molnupiravir, fluvoxamine and Paxlovid) are effective in reducing the mortality and hospitalization rates in patients with COVID-19. In addition, the three oral drugs did not increase the occurrence of adverse events, thus exhibiting good overall safety. These three oral antiviral drugs are still being studied, and the available data suggest that they will bring new hope for COVID-19 recovery and have the potential to be a breakthrough and very promising treatment for COVID-19.KEY MESSAGESMany antiviral drugs have shown good therapeutic effects, and there is no simple oral antiviral drug for COVID-19 patients.Meta-analysis was conducted for three new oral antivirals to evaluate the improvement in mortality or hospitalization rates and adverse events among COVID-19 patients.We focussed on three new oral Coronavirus agents (molnupiravir, fluvoxamine and Paxlovid) and hope to provide guidance for the roll-out of oral antivirals.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wen</LastName>
            <ForeName>Wen</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Hangzhou Institute of Cardiovascular Diseases, Affiliated Hospital of Hangzhou Normal University, Hangzhou, PR China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Hangzhou Normal University, Hangzhou, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Chen</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Hangzhou Institute of Cardiovascular Diseases, Affiliated Hospital of Hangzhou Normal University, Hangzhou, PR China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Hangzhou Normal University, Hangzhou, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Jiake</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Hangzhou Institute of Cardiovascular Diseases, Affiliated Hospital of Hangzhou Normal University, Hangzhou, PR China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Hangzhou Normal University, Hangzhou, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Chunyi</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Hangzhou Institute of Cardiovascular Diseases, Affiliated Hospital of Hangzhou Normal University, Hangzhou, PR China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Hangzhou Normal University, Hangzhou, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Mengyun</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular and Cellular Physiology, Shinshu University School of Medicine, Matsumoto, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cheng</LastName>
            <ForeName>Yongran</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>School of Public Health, Hangzhou Medical College, Hangzhou, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Xiang</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Hangzhou Institute of Cardiovascular Diseases, Affiliated Hospital of Hangzhou Normal University, Hangzhou, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Qi</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Hangzhou Institute of Cardiovascular Diseases, Affiliated Hospital of Hangzhou Normal University, Hangzhou, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Xingwei</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Hangzhou Institute of Cardiovascular Diseases, Affiliated Hospital of Hangzhou Normal University, Hangzhou, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Feng</LastName>
            <ForeName>Zhanhui</ForeName>
            <Initials>Z</Initials>
            <Identifier Source="ORCID">0000-0003-4755-7415</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Affiliated Hospital of Guizhou Medical University, Guiyang, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Mingwei</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0001-9060-5107</Identifier>
            <AffiliationInfo>
              <Affiliation>Hangzhou Institute of Cardiovascular Diseases, Affiliated Hospital of Hangzhou Normal University, Hangzhou, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mao</LastName>
            <ForeName>Qin</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Hangzhou Institute of Cardiovascular Diseases, Affiliated Hospital of Hangzhou Normal University, Hangzhou, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D017418">Meta-Analysis</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Ann Med</MedlineTA>
        <NlmUniqueID>8906388</NlmUniqueID>
        <ISSNLinking>0785-3890</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006898">Hydroxylamines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007769">Lactams</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009570">Nitriles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000719967">nirmatrelvir and ritonavir drug combination</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5CSZ8459RP</RegistryNumber>
          <NameOfSubstance UI="D003562">Cytidine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9DLQ4CIU6V</RegistryNumber>
          <NameOfSubstance UI="D011392">Proline</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>GMW67QNF9C</RegistryNumber>
          <NameOfSubstance UI="D007930">Leucine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>O3J8G9O825</RegistryNumber>
          <NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>O4L1XPO44W</RegistryNumber>
          <NameOfSubstance UI="D016666">Fluvoxamine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>YA84KI1VEW</RegistryNumber>
          <NameOfSubstance UI="C000656703">molnupiravir</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <SupplMeshList>
        <SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003562" MajorTopicYN="N">Cytidine</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016666" MajorTopicYN="Y">Fluvoxamine</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006898" MajorTopicYN="N">Hydroxylamines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007769" MajorTopicYN="N">Lactams</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007930" MajorTopicYN="N">Leucine</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009570" MajorTopicYN="N">Nitriles</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011392" MajorTopicYN="N">Proline</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">COVID-19</Keyword>
        <Keyword MajorTopicYN="Y">Paxlovid™</Keyword>
        <Keyword MajorTopicYN="Y">fluvoxamine</Keyword>
        <Keyword MajorTopicYN="Y">molnupiravir</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>4</Day>
          <Hour>8</Hour>
          <Minute>41</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35118917</ArticleId>
        <ArticleId IdType="pmc">PMC8820829</ArticleId>
        <ArticleId IdType="doi">10.1080/07853890.2022.2034936</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>WHO . Coronavirus (COVID-19) data . [cited 2021 Nov 12]. Available from: https://www.who.int/data#reports</Citation>
        </Reference>
        <Reference>
          <Citation>Rivasi G, Bulgaresi M, Mossello E, et al. . 
Course and lethality of SARS-CoV-2 epidemic in nursing homes after vaccination in Florence, Italy. Vaccines (Basel). 2021;9(10):1174.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8537408</ArticleId>
            <ArticleId IdType="pubmed">34696282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>National health commission of the people's republic of China. [cited 2021 Nov 12]. Available from: http://www.nhc.gov.cn/jkj/s7915/202111/fc017abab2af4dfbbe5b4f0bdcbf8795.shtml</Citation>
        </Reference>
        <Reference>
          <Citation>Imran M, Kumar Arora M, Asdaq SMB, et al. . 
Discovery, development, and patent trends on molnupiravir: a prospective oral treatment for COVID-19. Molecules. 2021;26(19):5795.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8510125</ArticleId>
            <ArticleId IdType="pubmed">34641339</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Christie A, Mbaeyi SA, Walensky RP.. 
CDC interim recommendations for fully vaccinated people: an important first step. JAMA. 2021;325(15):1501–1502.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33688914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vitiello A, Troiano V, La Porta R.. 
What will be the role of molnupiravir in the treatment of COVID-19 infection?
Drugs Ther Perspect. 2021;37(12):572–579.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8570236</ArticleId>
            <ArticleId IdType="pubmed">34754175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferner RE, Aronson JK.. 
Remdesivir in covid-19. BMJ. 2020;369:m1610.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32321732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vitiello A, Ferrara F, Porta R. Remdesivir and COVID-19 infection, therapeutic benefits or unnecessary risks? Ir J Med Sci. 2021;190(4):1637–1638.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7801863</ArticleId>
            <ArticleId IdType="pubmed">33433843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Menéndez-Arias L.
Decoding molnupiravir-induced mutagenesis in SARS-CoV-2. J Biol Chem. 2021;297(1):100867.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8188802</ArticleId>
            <ArticleId IdType="pubmed">34118236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao J, Guo S, Yi D, et al. . 
A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase. Antiviral Res. 2021;190:105078.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8059291</ArticleId>
            <ArticleId IdType="pubmed">33894278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agostini ML, Pruijssers AJ, Chappell JD, et al. . 
Small-Molecule antiviral β-d- N 4-Hydroxycytidine inhibits a Proofreading-Intact coronavirus with a high genetic barrier to resistance. J Virol. 2019;93(24):e01348–19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6880162</ArticleId>
            <ArticleId IdType="pubmed">31578288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosenke K, Hansen F, Schwarz B, et al. . 
Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model. Nat Commun. 2021;12(1):2295.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8052374</ArticleId>
            <ArticleId IdType="pubmed">33863887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sheahan TP, Sims AC, Zhou S, et al. . 
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Trans Med. 2020;12(541):eabb5883.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7164393</ArticleId>
            <ArticleId IdType="pubmed">32253226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fischer W, Eron JJ, Holman W, et al. . 
Molnupiravir, an oral antiviral treatment for COVID-19. medRxiv. 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Mahase E.
Covid-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports. BMJ. 2021;375:n2422.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34607801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calusic M, Marcec R, Luksa L, et al. . 
Safety and efficacy of fluvoxamine in COVID-19 ICU patients: an open label, prospective cohort trial with matched controls. Br J Clin Pharmacol. 2021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8653355</ArticleId>
            <ArticleId IdType="pubmed">34719789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seftel D, Boulware DR.. 
Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19. Open Forum Infect Dis. 2021;8(2):ofab050.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7888564</ArticleId>
            <ArticleId IdType="pubmed">33623808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lenze EJ, Mattar C, Zorumski CF, et al. . 
Fluvoxamine vs. placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA. 2020;324(22):2292–2300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7662481</ArticleId>
            <ArticleId IdType="pubmed">33180097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reis G, Dos Santos Moreira-Silva EA, Silva DCM, et al. . 
Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health. 2022;10(1):e42–e51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8550952</ArticleId>
            <ArticleId IdType="pubmed">34717820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pfizer’s novel COVID-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study . 2021. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate</Citation>
        </Reference>
        <Reference>
          <Citation>Hetero announces interim clinical results from phase III clinical trials of molnupiravir conducted in India . 2021. Available from: https://c19mp.com/hetero.html</Citation>
        </Reference>
        <Reference>
          <Citation>Singh AK, Singh A, Singh R, et al. . 
Molnupiravir in COVID-19: a systematic review of literature. Diabetes Metab Syndr. 2021;15(6):102329.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8556684</ArticleId>
            <ArticleId IdType="pubmed">34742052</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toots M, Yoon JJ, Hart M, et al. . 
Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model. Trans Res. 2020;218:16–28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7568909</ArticleId>
            <ArticleId IdType="pubmed">31945316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kabinger F, Stiller C, Schmitzová J, et al. . 
Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat Struct Mol Biol. 2021;28(9):740–746.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8437801</ArticleId>
            <ArticleId IdType="pubmed">34381216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou S, Hill CS, Sarkar S, et al. . 
β-d-N4-hydroxycytidine inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells. J Infect Dis. 2021;224(3):415–419.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8136050</ArticleId>
            <ArticleId IdType="pubmed">33961695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sukhatme VP, Reiersen AM, Vayttaden SJ, et al. . 
Fluvoxamine: a review of its mechanism of action and its role in COVID-19. Front Pharmacol. 2021;12:652688.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8094534</ArticleId>
            <ArticleId IdType="pubmed">33959018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>8 Lingering questions about the new Covid pills from Merck and Pfizer . [cited 2021 Nov 16]. Available from: https://www.statnews.com/2021/11/15/8-lingering-questions-about-the-new-covid-pills-from-merck-and-pfizer/</Citation>
        </Reference>
        <Reference>
          <Citation>Pfizer seeks emergency use authorization for novel COVID-19 oral antiviral candidate . Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-seeks-emergency-use-authorization-novel-covid-19</Citation>
        </Reference>
        <Reference>
          <Citation>Painter WP, Holman W, Bush JA, et al. Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel Broad-Spectrum oral antiviral agent with activity against SARS-CoV-2. Antimicrob Agents Chemother. 2021;65(5):e02428–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8092915</ArticleId>
            <ArticleId IdType="pubmed">33649113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pormohammad A, Zarei M, Ghorbani S, et al. . 
Efficacy and safety of COVID-19 vaccines: a systematic review and Meta-Analysis of randomized clinical trials. Vaccines (Basel). 2021;9(5):467.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8148145</ArticleId>
            <ArticleId IdType="pubmed">34066475</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharif N, Alzahrani KJ, Ahmed SN, et al. . 
Efficacy, immunogenicity and safety of COVID-19 vaccines: a systematic review and Meta-Analysis. Front Immunol. 2021;12:714170.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8542872</ArticleId>
            <ArticleId IdType="pubmed">34707602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wibmer CK, Ayres F, Hermanus T, et al. . 
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med. 2021;27(4):622–625.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33654292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia-Beltran WF, Lam EC, St Denis K, et al. . 
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021;184(9):2372–2383.e9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7953441</ArticleId>
            <ArticleId IdType="pubmed">33743213</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
